Private equity giant KKR has emerged victorious in the takeover battle for British scientific instruments manufacturer Spectris, securing the deal with a £4.7 billion bid that outstripped rival Advent International’s £4.4 billion offer. This acquisition, which is now the largest UK takeover target of 2025, underscores the increasing appetite of private equity in UK-listed companies, particularly those perceived to have untapped growth potential that public markets have yet to fully realise.

The Spectris board formally withdrew its previous support for Advent’s bid in favour of the higher cash offer from KKR, which values the company at £40 per share, including an interim dividend of 28 pence. This offer represents a premium of approximately 96% over Spectris’s share price prior to the takeover interest announcement. The move sparked a positive reaction from investors, with Spectris shares climbing over 5%, reaching their highest level in more than three and a half years. The deal will be implemented through a court-sanctioned scheme of arrangement, expected to complete by early 2026, subject to shareholder, court, and regulatory approvals in multiple jurisdictions.

Spectris, a FTSE 250-listed firm, specialises in high-tech instruments and testing equipment used in diverse sectors such as pharmaceuticals, semiconductors, aerospace, and automotive manufacturing. The company reported sales of £1.2 billion and an adjusted operating profit of £203 million for the year ended December 2024. Despite its steady financials, KKR believes that Spectris has not fully realised its growth potential under its public ownership. The private equity firm has signalled intentions to introduce initiatives such as employee ownership schemes, aiming to foster alignment and motivation among the workforce while driving future expansion.

This takeover is part of a broader wave of private equity interest and mergers in the UK market. The acquisition reflects a continuing trend of foreign investment seeking opportunity amid attractive UK valuations and equity market conditions. It comes amid a flurry of significant deals, including the recent acquisitions of companies like the GP surgery owner Assura and microchip designer Alphawave by major US firms, underscoring London’s vibrant but increasingly contested market landscape. Meanwhile, KKR’s reputation as the ‘barbarians at the gate,’ originating from their formidable 1989 bid for RJR Nabisco, continues to colour perceptions of its aggressive and strategic approach to acquisitions.

The deal adds to a growing tally of UK firms departing the London Stock Exchange through private equity buyouts. Industry observers note the private equity sector’s adaptation of roll-up strategies, combining smaller firms to create scalable and efficient entities, a practice increasingly evident in wealth management and technology sectors as well. Notably, KKR, while successful here, recently lost out on the NHS property group Assura to a competing bid, showing the competitive nature of such takeovers continues.

Speakers involved expressed confidence in the transaction. Spectris chairman Mark Williamson described KKR’s offer as delivering “attractive and immediate cash value for shareholders” alongside “a compelling vision for the future of the group.” The previous bidder Advent has not publicly responded following the withdrawal of the board’s support, and analysts suggest further contestation is unlikely given its multiple bid increases.

With this acquisition, Spectris is set to delist from the London market and operate as a private company under KKR’s ownership, reflecting a growing trend of public-to-private transactions in the UK amid what some see as a challenging public market environment.

📌 Reference Map:

Source: Noah Wire Services